107 results about "Seizure Disorders" patented technology

A patient management system can include an implantable neurostimulation device configured to deliver vagus nerve stimulation (VNS) therapy to a patient and a non-invasive, external monitoring device comprising at least one sensor for detecting indicators of seizure or depression in the patient. In an example, the external monitoring device is configured to use information from the at least one sensor to detect a seizure event or a seizure precursor event, audibly ask questions of the patient and / or provide behavioral modification commands to the patient, and / or control the neurostimulation device to deliver the VNS therapy to the patient in response to a detected seizure event, seizure precursor event, or progression of depression symptoms.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The present invention relates to a novel class of bicyclic derivatives that function as small-molecule KCQN2 / 3 (Kv7.2 / 3) potassium channel activators, along with their pharmaceutical composition, method of preparation, and therapeutic applications. These compounds, represented by Formula (I), and defined by specific substituents and structural characteristics as described in the specification. By modulating or enhancing the activation of Kv7.2 / 3 potassium channels, these derivatives hold therapeutic potential for treating seizure disorders and other conditions influenced by potassium ion channel modulation.

In certain embodiments, the present disclosure is directed to methods for treating disorders, including depressive disorders, seizure disorders, and anhedonia, in a pediatric subject, wherein the methods comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, A-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6- dimethylphenyl]-3,3-dimethylbutanamide (azetukalner), or a pharmaceutically acceptable salt thereof, to the pediatric subject, for example, under fed conditions.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Compositions and methods for treating a seizure disorder with a compound according to Formula (I), or pharmaceutically acceptable salts thereof, are provided. The compositions and methods may be used to improve one or more symptoms of a seizure disorder. Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone / sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone / sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

To provide compositions and methods for treating and preventing cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, and addiction.SOLUTION: Also provided are methods for the diagnosis and monitoring of cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, addiction, and other conditions such as convulsion or seizure. These compositions comprise fatty acid compounds and salts thereof which may be administered either alone, in combination with other medicaments, or as part of various treatment regimens. The provided compositions are effective for modulating markers, including, but not limited to, behavior associated with cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, opiate addiction, and other related conditions. Methods for administering the compositions are also provided.SELECTED DRAWING: Figure 1

Provided herein are methods for selecting a subject with a seizure disorder for treatment, as well as methods of treating the subject, determining the efficacy of the treatment, and adjusting the treatment dosage and frequency. In some aspects, provided herein are methods of treating seizures in a subject by administering to the subject a composition comprising bacteria of the Akkermansia (Akk) and Parabacteroides (Pb) genera.

Described herein are methods, compositions, products, and processes that utilize bioceramics in traditional agricultural and hydroponic systems. The bioceramics are utilized in powder form, as films, as aerosols, as water based treatment systems, or in solid forms. The methods and bioceramic compositions described here are also used for growing a Cannabis plant. One or more cannabinoids within the plant can be used in therapeutic compositions for the treatment of glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

To provide compounds that prevent differentiation of cells and promote cell survival, including but not limited to, when the cells are isolated or are otherwise outside their normal medium or tissue milieu, in relation to compounds for stabilizing cells and their method of use.SOLUTION: Two classes of small molecular compounds shown in the selected drawing, by somewhat different mechanisms, both are useful as prophylactic and therapeutic compounds for a number of different disease indications, including but not limited to, cancer, tissue damage, and stroke.SELECTED DRAWING: Figure 1A

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

The present invention relates to antisense oligonucleotides capable of modulating the expression of Tau in a target cell. The oligonucleotide lines hybridize to the MAPT mRNA. The present invention further relates to conjugates of the oligonucleotides, and pharmaceutical compositions and methods for the treatment of a Tau aberrant deposition lesion (Tauopathy), Alzheimer's disease (AD), frontotemporal dementia (FTD), FTDP-17, progressive ocular nuclear paralysis (PSP), chronic traumatic brain lesion (CTE), corticobasal nuclear degeneration (CBD), epilepsy, a Display syndrome, depression, a seizure disorder (disorder of epileptic seizure), and a movement disorder (disorder of movement).

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

The present disclosure encompasses novel benzamide enaminone compounds and pharmaceutically acceptable salts thereof and compositions including such compounds and pharmaceutically acceptable salts. The disclosure further encompasses methods of treating a subject at risk of having a seizure and / or methods of reducing or preventing the occurrence or severity of a seizure or seizure disorder associated therewith by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof or a composition thereof. In some embodiments, the disclosure encompasses compositions and combinations of agents that act synergistically to treat, prevent, or inhibit the occurrence of a seizure or a seizure disorder.

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

Compositions comprising 0.1 to 50% delta-9-tetrahydrocannabinol and / or cannabidiol, the forms of which are suitable for continuous delivery, and their use in the treatment of various diseases and pathological conditions are disclosed. In a preferred embodiment, the composition is in a form suitable for delivery by a portable infusion pump or transdermal patch. The conditions to be treated include pain, cancer, seizure conditions, and Parkinson's disease. The composition may optionally further comprise an additional active agent, such as a dopaminergic agent, depending on the condition to be treated.

Provided herein are methods of treating a seizure disorder in a subject in need thereof comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Also provided are methods of treating a pain, neurological, or psychiatric disorder, and methods of administering seletracetam to a subject comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Various pharmaceutical formulations comprising seletracetam, e.g., an orally disintegrating tablet and a mucoadhesive film, and a nasal spray device or oromucosal spray device comprising seletracetam are also provided.

Provided are methods of treating a subject with a SCN2A-related disorder, e.g., Developmental and Epileptic Encephalopathies (DEE), comprising administering to the subject an oligomeric compound. Also provided are methods of reducing frequency of seizures experienced by a subject with a SCN2A-related disorder, comprising administering to the subject an oligomeric compound.

Methods and compositions for treating a patient suffering from Huntington's disease or treating symptoms thereof are disclosed. The methods comprise administering to the patient an effective amount of a heteroaryl ketone fused aza-naphthane glucocorticoid receptor modulator (GRM) or an octahydro fused aza-naphthane GRM. In an embodiment, the GRM is Dargencolan. In some embodiments, the GRM is zaltile blue. In embodiments, the GRM is administered orally. In some embodiments, the GRM is administered daily; in other embodiments, the GRM is administered in a regimen, such as once every day, once every three days, once per week, or other administration regimen. The symptoms of Huntington's disease that can be treated by the methods described herein include, but are not limited to, motor symptoms (e.g., muscle weakness, posture abnormalities, walking difficulty, dysphagia) and neurological or psychological symptoms (e.g., seizure, amnesia, consciousness disorder, impaired verbal ability, delirium, depression, anxiety).

The present invention provides N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, e.g., as receptor probes, as neurotransmission modulators, and as therapeutic agents, e.g., as central nervous system drugs. Also provided are pharmaceutical compositions and methods for their use in the treatment of certain diseases, such as serotonin neurotransmitter diseases, mental health disorders, and ion channel mediated diseases, such as seizure disorders.

The present invention provides the use of Ly93 in the preparation of anti-seizure drugs, providing a new idea for seizure treatment drugs. The research results of the present invention show that Ly93 can significantly reduce the seizure grade in the KA-induced mouse seizure model, can significantly reduce the seizure duration induced by PTZ, Ly93 can significantly inhibit neuroinflammation during seizures, and Ly93 does not affect the body weight of mice. Therefore, Ly93 has significant effects as a seizure treatment drug, has good safety, and has small toxic and side effects.

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) with DEPDC5 gene mutation. In a further embodiment the types of seizures include tonic, tonic-clonic and focal seizures without impairment. Preferably the dose of CBD is between 5 mg / kg / day to 50 mg / kg / day.

Compositions and methods for treating a seizure disorder with a compound according to Formula (I), or pharmaceutically acceptable salts thereof, are provided. The compositions and methods may be used to improve one or more symptoms of a seizure disorder.Formula (I):or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.